Lantheus (NASDAQ:LNTH) Posts Earnings Results

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50, FiscalAI reports. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The firm had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. During the same quarter in the prior year, the firm earned $1.59 EPS. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus’ conference call:

• Lantheus has refocused on PET radiodiagnostics, completing acquisitions of Neuraceq and OCTEVY and divesting its legacy SPECT business, which management says diversifies near‑term revenue and leaves the company with the broadest radiodiagnostic pipeline among peers.
• Management expects multiple near‑term regulatory milestones — PDUFA for the new PSMA F‑18 formulation (Mar 6), OCTEVY (Mar 29), MK‑6240 (Aug 13) and a mid‑year Hatch‑Waxman ruling for PNT2003 — and plans a regional PMF rollout of the new PSMA formulation in Q4 2026, with material commercial impact beginning in 2027.
• Reported Q4 revenue was $406.8M and FY‑2025 revenue $1.5416B; guidance for 2026 is $1.4–$1.45B in revenue and EPS of $5.00–$5.25, while management also expects PYLARIFY net revenue to decline ~8%–10% in 2026 as modest price erosion offsets volume.
• Cash generation weakened — Q4 operating cash flow fell to $90.2M (from $157.7M) and free cash flow to $81.4M — while the company incurred ~$21.7M of acquisition/integration/divestiture costs and other charges; it did repurchase $100M of shares and ended the quarter with ~$359.1M in cash.

Lantheus Price Performance

LNTH traded down $0.52 during trading on Friday, reaching $74.91. 1,380,211 shares of the company traded hands, compared to its average volume of 837,925. The company has a market cap of $4.97 billion, a P/E ratio of 22.23 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29. The firm has a fifty day simple moving average of $68.15 and a 200 day simple moving average of $60.14.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Truist Financial set a $89.00 price target on shares of Lantheus in a research note on Friday. Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. William Blair raised Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday. Finally, JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.17.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in Lantheus during the second quarter valued at approximately $36,000. Parallel Advisors LLC grew its holdings in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Lantheus in the 4th quarter worth approximately $39,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $55,000. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.